I., & Yang, S
Oral administration of PF-06882961 shows evidence of glucose-lowering in healthy human study participants PF-06882961 was selected as a candidate for clinical studies based on its in vitro and in vivo pharmacologic and disposition profile, including potent agonism of the GLP-1R, preclinical disposition attributes (e.g., low metabolic CL int in human hepatocytes), good safety margins versus the hERG channel (IC 50 = 4.3 M, Table S4) and broad panel screening (Table S8), and selectivity versus related class B GPCRs (Table S9)
The rise of #NaturalHairstyling points to a demand for effortless, texture-embracing styles, while #BlackLipLiner signals growing interest in bold, high-contrast makeup choices
[DOI] [PMC free article] [PubMed] [Google Scholar] 41.Majeed M., Ahmed F., Teeling M
Melanotan-2 remains an early-stage research compound with limited clinical data, significant safety concerns documented in case reports, and no path to regulatory approval for its commonly promoted uses (tanning and sexual enhancement)
Another phase III, randomized, open-label, non-inferiority, head-to-head trial, AWARD-6, evaluated dulaglutide (1.5 mg) versus liraglutide (1.8 mg) in patients with T2DM
